Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.41 |
| ▸ | CES1 | P23141 | 4/20 | 0.41 |
| ▸ | FABP3 | P05413 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioglycolic Acid SCHEMBL33524973 | 0.92 | CA1 (0.43) | CES2CES1FABP3CA1CA2 | |
| Thioglycolic Acid SCHEMBL6365844 | 0.86 | CES2 (0.43) | CES2CES1FABP3CA1GPR84 | |
| Thioglycolic Acid SCHEMBL7654255 | 0.86 | CES2 (0.43) | CES2CES1FABP3CA1GPR84 | |
| 1,4-Butanediol SCHEMBL8778129 | 0.79 | LMNA (0.46) | CES2CES1FABP3CA1KMT2A | |
| Thioglycolic Acid SCHEMBL7731764 | 0.77 | CES2 (0.46) | CES2CES1FABP3CA1GPR84 | |
| Thioglycolic Acid SCHEMBL746612 | 0.77 | CA1 (0.44) | CES2CES1FABP3CA1CA2 | |
| Fumaric Acid SCHEMBL11672387 | 0.77 | FABP3 (0.39) | CES2CES1FABP3CA1 | |
| Thioglycolic Acid SCHEMBL9833354 | 0.75 | CES2 (0.44) | CES2CES1FABP3CA1GPR84 | |
| Thioglycolic Acid SCHEMBL10800355 | 0.75 | CES2 (0.44) | CES2CES1FABP3CA1GPR84 | |
| Thioglycolic Acid SCHEMBL10800359 | 0.75 | CES2 (0.44) | CES2CES1FABP3CA1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729526-A2 | BIS(ALKYLTIN MERCAPTIDES) AND THEIR USE AS HEAT STABILIZERS | Galata Chemicals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260092210-A1 | BIS(ALKYLTIN MERCAPTIDES) AND THEIR USE AS HEAT STABILIZERS | GALATA CHEMICALS LLC (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092210-A1 | BIS(ALKYLTIN MERCAPTIDES) AND THEIR USE AS HEAT STABILIZERS | MGMT, TST, MPST | CES2 279/4885CES1 464/4885FABP3 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.